


Blue Ribbon Commission on America's Nuclear Future Subcommittee on Reactor and Fuel Cycle Technology

A Venture Capital Point of View

Ray A. Rothrock August 30, 2010

Ray A. Rothrock



- Venrock, Managing General Partner
 - + VC for 22 years, 47 deals, 94% IRR
 - + Established energy practice 2004
 - Nuclear Engineer



- + Professional Nuclear Engineer, 1978-81
- + Transient Safety & Licensing Engineer for Yankee Rowe, Rowe, Mass '78-'80
- + Exxon Nuclear, '80-'81
- National Venture Capital Association Executive Committee & Director
- MIT Visiting Committee Nuclear Science and Engineering, 8 years
- Tri Alpha Energy, Chairman of Board



Venture Capital in the United States

Mission

Identify and sponsor entrepreneurs with world changing ideas

Benefit

Allocate scarce capital plus human resources towards opportunities

Venture Capital at Work

- 792 firms nationwide
- Over 2000 new companies financed each year
- \$180B under management

Results as of 2009

(Thomson Reuters data)

- \$2.9T revenue (22% of GDP)
- 12.1 million jobs (11% of private sector)



VENTURE CAPITAL **BUILDS COMPANIES** THAT SHAPE THE







































Regulatory Environment Perspective



Department of Energy

- Weapons management
- Waste management
- Basic science
- Principal source of funds for private efforts in alternative energy



Regulatory Environment Perspective



Department of Energy

- Weapons management
- Waste management
- Basic science
- Principal source of funds for private efforts in alternative energy



Nuclear Regulatory Commission

- Nuclear materials focus
- No focus on electricity
- Wealth of nuclear experience - retiring
- No risk/reward paradigm

Regulatory Environment Perspective



Department of Energy

- Weapons management
- Waste management
- Basic science
- Principal source of funds for private efforts in alternative energy



Nuclear Regulatory Commission

- Nuclear materials focus
- No focus on electricity
- Wealth of nuclear experience - retiring
- No risk/reward paradigm




Neither regulatory body is focused on nuclear power as applied to production of electricity





A Government/Venture Success Story





- + Worthy products get to market in a timely manner
- + Works actively with the private sector
- + Informs the public with science-based information



FDA New Drug Process

Illustration

Stage	Elapsed Time (Years)	Capital Requirement (Millions)	Purpose	Market Value (Millions)	Probability of Continuing
Pre-Clinical	1-5	\$10-\$50	Pre-human validation	\$10-\$20	10%
Phase I	1-2	\$5-\$20	Safety	\$10-\$50	65%
Phase II	2	\$20-\$50	Efficacy and dose	\$50-\$100	50%
Phase III	3	\$40-\$100	Registration Trial	\$200-\$400	65%
NDA	1	\$20-\$50	Manufacturing	\$500-\$1000	90%



Benefits: Orderly, Predictable, Finite, Conclusive



Economic Recommendations

- Mational carbon-tax
 - 1) Source tax (not use)
 - 2) Levels playing field
 - 3) Sets standards for economics
 - 4) Achievable, understandable, predictable
- M Fee Based Review
 - 1) No per hour charge back
 - 2) Risk/reward consideration



Wenrock

Building companies that shape the future